High Cure Rates and Reduced Long-Term Toxicity in Pediatric Hodgkin's Disease: The German-Austrian Multicenter Trial DAL-HD-90

Abstract

OEPA is a satisfactory alternative to OPPA. Radiotherapy can be confined to involved sites when combined with appropriate chemotherapy. The DAL-HD-90 regimen represents a comprehensive treatment program for all stages of pediatric HD and offers a favorable benefit/risk ratio, combining excellent disease control, moderate acute toxicity, and reduced long-term toxicity.

Número de áreas anatômicas envolvidas como preditor de risco no linfoma de Hodgkin em crianças: um estudo retrospectivo

“…In respect to clinical outcome, our results with a risk-adapted, homogeneously treated group of patients achieved survival rates comparable to those obtained in developed countries 2,5,24,25 and in the most developed region of Brazil. 21 The late effects were also similar to those described in other studies that treated children with the same protocols.…”

Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer

“…Renal function was evaluated in 160 serum and urine samples obtained from 66 children with various tumors ( [8][9][10][11][12][13][14][15] Progressive damage caused by consecutive DNR treatment was examined in 26 patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL) (boys:girls=20:6, all Caucasians, mean age: 8.7±4.5 years, age range: 2-18.0 years, median:7.0 years). Children with standard-risk (SR) ALL and NHL received 2, children with intermediate-(IR) and high-risk (HR) ALL received 4 courses of DNR, as indicated by the treatment protocol.…”

Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G1 phase

“…The details and treatment regimens of these studies have been outlined in detail. 22,23 Briefly, in both treatment protocols, the therapy consisted of combined radio-chemotherapy regimens stratified into three treatment groups (TG) based on clinical stage, presence of B symptoms and extranodal disease. Patients with localized disease (TG 1: stages I, IIA), intermediate stages (TG 2: stages II E A, IIB, IIIA) and advanced stages (TG 3: stages II E B, IIIB, III E, IV) initially received two, four or six cycles of polychemotherapy, respectively.…”